How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
Start by identifying the research stage and exact molecule. Then examine the comparison group, participant selection, endpoint, follow-up, missing data, adverse-event reporting, and funding. A statistically detectable result may still be small, uncertain, or irrelevant to patient goals. For background on the field, see this NIH-hosted therapeutic peptide review.
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
BDNF
An evidence-first reference for reading claims and source material about BDNF.
Open resourcePeptide briefDihexa
An evidence-first reference for reading claims and source material about Dihexa.
Open resourcePeptide briefDihexa / Tesofensine / BPC-157
An evidence-first reference for reading claims and source material about Dihexa / Tesofensine / BPC-157.
Open resourcePeptide briefDSIP
An evidence-first reference for reading claims and source material about DSIP.
Open resourcePeptide briefMethylene Blue / Methylliberine
An evidence-first reference for reading claims and source material about Methylene Blue / Methylliberine.
Open resourcePeptide briefOxytocin
An evidence-first reference for reading claims and source material about Oxytocin.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resource